A third 4-1BB CAR-T cell product, Idecabtagene Vicleucel, the first FDA-approved CAR-T cell therapy for multiple myeloma, is targeting the B cell maturation antigen (BCMA) expressed on multiple myeloma cells. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.